Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024, Chicago, USA.
The scientific session scheduled at Neuroscience 2024 will provide the comprehensive findings from the Phase-2a proof-of-concept signal detection open label study of Ropanicant.
Suven plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025.
Join us at exhibit booth # 1666 at Neuroscience 2024 to learn about the latest advancements in Suven Innovation pipeline.
Hyderabad, India (3-Oct-2024): Suven Life Sciences Ltd (Suven) announces five presentations covering clinical and pre-clinical assets from their portfolio of new chemical entities at the upcoming Neuroscience 2024 conference, taking place during October 5-9, 2024, in Chicago, Illinois, USA. Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN), will bring together neuroscientists from around the globe, representing leading Pharma, Biotech and Clinical Research institutes.
Presentation Titles:
- Ropanicant (SUVN-911), an α4β2 nAChR Antagonist: A Phase-2 Study Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder.
- Samelisant (SUVN-G3031): Safety and Efficacy Outcome from the Phase-2 Proof-ofConcept, Double-Blind, Placebo-Controlled Study in Patients with Narcolepsy.
- Rationale and Study Design for the Phase-3 Clinical Development Program of Masupirdine (SUVN-502), a Pure 5-HT6 Receptor Antagonist, for the Treatment of Agitation in Patients with Dementia of Alzheimer's Type.
- Dual 5-HT1A and 5-HT2A Receptor Ligand SUVN-2206043 shows Antipsychotic and Antidepressant Like Effects in Animal Models.
- SUVN-L3307032, a Positive Allosteric Modulator (PAM) at Muscarinic M4 Receptor for the Treatment of Psychotic Symptoms.
Suven is showcasing its Innovation Pipeline and comprehensive summaries at Neuroscience 2024 at exhibit booth # 1666.
Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 145.85 as compared to the previous close of Rs. 140.65. The total number of shares traded during the day was 16176 in over 578 trades.
The stock hit an intraday high of Rs. 146.90 and intraday low of 137.85. The net turnover during the day was Rs. 2293937.00. |
